Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + SOX neoadjuvant phase II study in PD-L1-negative upper gastric/GEJ cancer
ChiCTR2400079586Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jan 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, tegafur and oxaliplatin in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Chinese PLA General Hospital. Primary endpoint: Pathological complete response rate. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
cadonilimabtegafuroxaliplatin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400079586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079586.